
|Articles|April 1, 2003
Time and the Bottom Line
Ponder this oh-so-common catch-22. Have you ever requested authorization from an insurance company to do a procedure on a patient and received a comment that they won't approve the procedure, but they will consider payment after the procedure has been performed? Or have your patients been denied approval when they have a medically necessary or medically related condition that should be legitimately approved?
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
3
Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"
4
Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses
5










